Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab.
Roberta LoveikyteArno R BourgonjeJohannes J van der ReijdenMarian L C BulthuisLukas J A C HawinkelsMarijn C VisschedijkEleonora A M FestenHendrik M van DullemenRinse K WeersmaHarry van GoorAndrea E van der Meulen-de JongGerard DijkstraPublished in: Inflammatory bowel diseases (2023)
Hepcidin levels in IBD are primarily determined by ID, even in an inflammatory state. In addition, induction therapy can decrease hepcidin levels, which might lead to better bioavailability of iron supplements. Therefore, hepcidin is a potential diagnostic ID biomarker that could assist therapeutic decision making.